Table 4.

Parameters reported to correlate with clinical outcomes after HCT (adapted from Geddes et al [811] with publisher’s permission). Additional studies are needed before any one of the immune tests presented here can be recommended for use in decision-making on infection prophylaxis (see text)

Parameter (Ref.)	Timing	Result	Outcome	Multivariate analysis
Lymphocyte count [812,813]	Day 15	<500/μl	Decreased OS and PFS (autologous HCT)	Yes
Lymphocyte count [814,815]	Day 30	<300/μl	Decreased OS and LFS, Increased NRM (allogeneic HCT)	Yes
B-cells and monocyte counts [816]	Day 80	Low (cutoff value not given)	Increased infections	Yes
CD4 T-cell count [59]	3 months	<200/μl	Decreased OS, Increased NRM and infections	Yes (OS and NRM), No (infections)
CD8 T-cell and B-cell counts [817]	6 months	Low (cutoff value not given)	Increased treatment failure (death, relapse or graft failure)	No
CMV peptide–specific CD8 T-cell counts* [818]	Every 2 weeks during days 0 to 65	<7 cells/ml in all samples	Increased risk of recurrent or persistent CMV reactivation	Not specified
CMV-specific lymphoproliferation [248]	4 months	Undetectable proliferation	Increased late CMV disease	No
NK-cell chimerism [815]	First 100 days	Incomplete chimerism	Decreased RFS	Yes
NK-cell count [819]	Day 15	<80/μl	Decreased OS and PFS (autologous HCT)	Yes
CD56high NK-cell count [820]	Day 14	<7/μl**	Decreased OS, increased NRM	Yes (OS), No (NRM)
Non-HLA genetics [821–824]	Pre-transplant	At risk allele in donor or recipient	Increased infections, survival	No

^*Assay measuring the quantity but not quality of CMV-specific T cells.

^**Patients were split into low, intermediate and high groups with cutoffs of 4/μl and 9/μl.

Abbreviations: OS – overall survival, PFS – progression-free survival, LFS – leukemia-free survival, NRM – non-relapse mortality, CMV - cytomegalovirus